person · Reporting owner

Gibney Anthony S

Disclosed activity across 5 companies

Tapewire entity: 37609
SEC CIK: 0001750132

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aura Biosciences, Inc.AURA · Entity 5142	See Remarks	June 16, 2026	June 16, 2026
Clearside Biomedical, Inc.CLSD · Entity 82875	Director	June 20, 2024	June 21, 2024
InflaRx N.V.IFRX · Entity 5840	Director	March 18, 2026	March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aura Biosciences, Inc.

Report date June 16, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	265,354	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Sale · Disposed 12,824 · Balance 265,354 F1: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Clearside Biomedical, Inc.

Report date June 20, 2024 · Filed June 21, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19	Direct	45,000	Reported balance After 2024-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.

InflaRx N.V.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,000	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 10,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2028-02-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: This option was granted on February 7, 2018 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2031-07-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2032-01-11	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F3: This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.37 · Expires 2033-01-24	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F4: This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2034-01-05	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F5: This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 · Expires 2035-01-03	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F6: This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2036-01-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F7: This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on February 7, 2018 and is fully vested and exercisable as of the date hereof.

F2: This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

F3: This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

F4: This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

F5: This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

F6: This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

F7: This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACHILLION PHARMACEUTICALS INC

Report date January 28, 2020 · Filed January 29, 2020

Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.53 · Expires 2028-08-15	Direct	0	Reported balance After 2020-01-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-28 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23	Direct	0	Reported balance After 2020-01-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.

IVERIC bio, Inc.

Report date July 11, 2023 · Filed July 13, 2023

Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-07-11 transaction · row 1 1 source row Row 1 · 2023-07-11 · Disposition to issuer · Disposed 40,291 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-11 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-07-11 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-11 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Each IVERIC performance restricted stock unit ("PSU") represented the contingent right to receive one share of Common Stock upon vesting of the PSU, based on the achievement of certain performance milestones. F5: Pursuant to the Merger Agreement, at the Effective Time, each PSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such PSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.16 · Expires 2031-12-12	Direct	Reported balance After 2023-07-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-07-11 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19	Direct	Reported balance After 2023-07-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-07-11 · Disposition to issuer · Disposed 50,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

F4: Each IVERIC performance restricted stock unit ("PSU") represented the contingent right to receive one share of Common Stock upon vesting of the PSU, based on the achievement of certain performance milestones.

F5: Pursuant to the Merger Agreement, at the Effective Time, each PSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such PSU.

F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 16, 2026 20:30 UTC	Aura Biosciences, Inc. AURA · Entity 5142	SaleCommon Stock	12,824	$6.42	$82,330.08	Disclosure SEC source: 0001193125-26-272703 · ownership.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,354 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:06 UTC	Aura Biosciences, Inc. AURA · Entity 5142	GrantStock Option (Right to Buy) · Derivative	128,755	$0.00 Strike: $6.14	$0.00	Disclosure SEC source: 0001193125-26-088168 · ownership.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,755 Underlying: Common Stock · 128,755 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:06 UTC	Aura Biosciences, Inc. AURA · Entity 5142	GrantCommon Stock	71,245	$0.00	$0.00	Disclosure SEC source: 0001193125-26-088168 · ownership.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,178 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:05 UTC	Aura Biosciences, Inc. AURA · Entity 5142	GrantStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $6.16	$0.00	Disclosure SEC source: 0000950170-25-081616 · ownership.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-06-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on May 13, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:05 UTC	Aura Biosciences, Inc. AURA · Entity 5142	GrantCommon Stock	150,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081616 · ownership.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,933 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on June 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
May 16, 2025 Filed May 20, 2025 21:34 UTC	Aura Biosciences, Inc. AURA · Entity 5142	PurchaseCommon Stock Warrants (right to buy) · Derivative	12,500	Not disclosed Strike: $4.90	Not disclosed	Disclosure SEC source: 0000950170-25-075403 · ownership.xml · derivative · entry 3 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-05-16 F1 · kind: On May 16, 2025, the Reporting Person purchased 50,000 shares of the Issuer's common stock and a warrant to purchase 12,500 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. F1 · price: On May 16, 2025, the Reporting Person purchased 50,000 shares of the Issuer's common stock and a warrant to purchase 12,500 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. Read SEC document
May 16, 2025 Filed May 20, 2025 21:34 UTC	Aura Biosciences, Inc. AURA · Entity 5142	SaleCommon Stock	1,519	$5.15	$7,822.85	Disclosure SEC source: 0000950170-25-075403 · ownership.xml · nonDerivative · entry 2 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,933 F2 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document
May 16, 2025 Filed May 20, 2025 21:34 UTC	Aura Biosciences, Inc. AURA · Entity 5142	PurchaseCommon Stock	50,000	$4.90	$245,000.00	Disclosure SEC source: 0000950170-25-075403 · ownership.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,452 F1 · kind: On May 16, 2025, the Reporting Person purchased 50,000 shares of the Issuer's common stock and a warrant to purchase 12,500 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:15 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $1.15	$0.00	Disclosure SEC source: 0001415889-24-017827 · form4-06212024_040618.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document
April 18, 2024 Filed Apr 19, 2024 13:45 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	PurchaseCommon Stock	93,290	$1.30	$121,277.00	Disclosure SEC source: 0001415889-24-011199 · form4-04192024_010400.xml · nonDerivative · entry 2 Gibney Anthony S · CIK 0001750132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.249 to $1.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 17, 2024 Filed Apr 19, 2024 13:45 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	PurchaseCommon Stock	6,710	$1.25	$8,387.50	Disclosure SEC source: 0001415889-24-011199 · form4-04192024_010400.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,710 Read SEC document
April 15, 2024 Filed Apr 16, 2024 20:31 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $1.29	$0.00	Disclosure SEC source: 0001415889-24-010873 · form4-04162024_080421.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-04-15 F1 · derivative.exercise_date: The shares underlying such option will vest in 36 equal monthly installments on the last day of each month commencing on April 30, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $22.57	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · derivative · entry 6 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-12-19 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	200,000	Not disclosed Strike: $15.16	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · derivative · entry 5 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2031-12-12 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	56,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · derivative · entry 4 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,250 shares Expires not disclosed F4 · derivative.exercise_price: Each IVERIC performance restricted stock unit ("PSU") represented the contingent right to receive one share of Common Stock upon vesting of the PSU, based on the achievement of certain performance milestones. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each PSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such PSU. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each PSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such PSU. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each PSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such PSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · derivative · entry 3 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	75,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerCommon Stock	40,291	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080680 · tm2321002-2_4seq1.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document
June 28, 2023 Filed Jun 30, 2023 16:17 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GiftCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000103 · wk-form4_1688156239.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,291 F1 · price: On June 28, 2023, the Reporting Person made a charitable donation of a total of 2,500 shares of Registrant's common stock. The Reporting Person no longer has a reportable beneficial interest in these shares. Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:54 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000145 · wf-form4_167175325765786.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:54 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $22.57	$0.00	Disclosure SEC source: 0001410939-22-000145 · wf-form4_167175325765786.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
December 13, 2022 Filed Dec 14, 2022 16:28 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000130 · wf-form4_167105328311833.xml · derivative · entry 4 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document
December 13, 2022 Filed Dec 14, 2022 16:28 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000130 · wf-form4_167105328311833.xml · derivative · entry 3 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: On December 13, 2021, the Reporting Person was granted 6,000 restricted stock units, which vested on the first anniversary of the grant date with respect to 100% of the shares. F3 · derivative.expiration_date: On December 13, 2021, the Reporting Person was granted 6,000 restricted stock units, which vested on the first anniversary of the grant date with respect to 100% of the shares. Read SEC document
December 13, 2022 Filed Dec 14, 2022 16:28 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000130 · wf-form4_167105328311833.xml · nonDerivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document
December 13, 2022 Filed Dec 14, 2022 16:28 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000130 · wf-form4_167105328311833.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · balance_after: This total includes 832 shares acquired by the Reporting Person on September 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported. Read SEC document
July 05, 2022 Filed Jul 5, 2022 18:30 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	7,791	$9.41	$73,313.31	Disclosure SEC source: 0001410939-22-000082 · wf-form4_165706020499268.xml · nonDerivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,959 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on June 30, 2022. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $9.37 to $9.47 on July 5, 2022 on behalf of the Reporting Person to satisfy the payment of withholding tax liability of the Reporting Person. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
June 30, 2022 Filed Jul 5, 2022 18:30 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	18,750	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000082 · wf-form4_165706020499268.xml · derivative · entry 3 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F5 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest based on the achievement of certain performance milestones. F5 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest based on the achievement of certain performance milestones. Read SEC document
June 30, 2022 Filed Jul 5, 2022 18:30 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	18,750	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000082 · wf-form4_165706020499268.xml · nonDerivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting upon the achievement of certain performance criteria, pursuant to the applicable Restricted Stock Unit Agreement. Read SEC document
December 13, 2021 Filed Dec 15, 2021 17:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-150045 · tm2135542-2_4seq1.xml · derivative · entry 4 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F5 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. Read SEC document
December 13, 2021 Filed Dec 15, 2021 17:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-150045 · tm2135542-2_4seq1.xml · derivative · entry 3 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F4 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest based on the achievement of certain performance milestones. F4 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest based on the achievement of certain performance milestones. Read SEC document
December 13, 2021 Filed Dec 15, 2021 17:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	100,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-150045 · tm2135542-2_4seq1.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document
December 13, 2021 Filed Dec 15, 2021 17:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $15.16	$0.00	Disclosure SEC source: 0001104659-21-150045 · tm2135542-2_4seq1.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:13 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	200,000	Not disclosed Strike: $2.18	Not disclosed	Disclosure SEC source: 0001562180-20-000671 · primarydocument.xml · derivative · entry 2 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:13 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	500,000	Not disclosed Strike: $2.53	Not disclosed	Disclosure SEC source: 0001562180-20-000671 · primarydocument.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2028-08-15 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document
January 23, 2019 Filed Jan 25, 2019 16:48 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantStock Option (Right to buy) · Derivative	200,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001209191-19-005367 · doc4.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document
August 15, 2018 Filed Aug 16, 2018 17:34 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantEmployee Stock Option · Derivative	500,000	$0.00 Strike: $2.53	$0.00	Disclosure SEC source: 0001209191-18-047147 · doc4.xml · derivative · entry 1 Gibney Anthony S · CIK 0001750132 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-08-15 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.